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clinical care (doctor-patient relationship, competence 
of nursing staff, etc.); 2) Satisfaction with physical 
surroundings (medical facilities, organisational structure,
etc.); 3) Satisfaction with clinical outcomes (result of
treatment, impairment due to side effects, etc.) In the
focus groups patients reported that analgesics and their
application forms have an impact on acceptance, com-
pliance, and on several areas of life such as sleep and life
style. CONCLUSIONS: The results of the focus groups
support the assumption, that at least one further dimen-
sion of patient’s satisfaction exists: satisfaction with
medical treatment. This aspect has not yet been taken up
by theoretical or empirical research. Due to this, world
wide there is no instrument for recording this dimension
today. The need to develop a new questionnaire to estab-
lish patients level of acceptance and satisfaction with 
their medication was speciﬁed and suggestions for a 4-
dimensional model of patient’s satisfaction were made.
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ABUSE TREATMENT OUTCOMES RESEARCH?
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OBJECTIVES: A lot of attention is focused on the
outcome effectiveness of substance abuse treatment. The
usual method of assessing outcomes is by contacting
clients after treatment and querying them on recovery-
related behaviors and on drug/alcohol use. Since
researchers are not always able to contact every client
after treatment, the issue of response bias is important.
Missing data is MAR, and thus ignorable, if differences
between respondents and nonrespondents can be charac-
terized by variables that are measured for both groups.
The objective of this research is to illuminate this issue by
using data collected from a U.S. treatment population and
to discuss statistical methods for correcting response bias.
METHODS: The data were collected from treatment
records and follow-up interviews of clients completing
substance abuse treatment at a facility in the U.S. Appro-
priate consent was obtained. Each client contacted was
administered a questionnaire. Eighty-eight (44.9%) com-
pleted the questionnaire; 102 (52.4%) could not be con-
tacted. Since the treatment records for the responders and
nonresponders were available, information was extracted
on variables related to treatment outcomes so that statis-
tical analysis could be conducted. RESULTS: No differ-
ences were found between responders and nonresponders
for most variables. Variables measuring demographics,
family support/structure, criminality/truancy, psychologi-
cal comorbidities, treatment attributes, and drug use were
not different. Variables with statistically signiﬁcant dif-
ferences were: “number of months at current residence”
(t = 2.12 p = .037) and the proportion “holding jobs”
(difference in proportions = .182; 95% CI = .043 to .321).
CONCLUSIONS: Missing data are not MAR, and thus
not ignorable, when missing variables are the same as or
related to variables that determine outcomes. In this case
“number of months at current residence” and “holding a
job” may predict treatment success. If this is true, some
method of control must be used. Weighting adjustments
such as post-stratiﬁcation and likelihood-based methods
are considered. Since the variables that predict treatment
outcomes are not fully understood, it is difﬁcult to be
certain MAR criteria are met.
METHODOLOGY ISSUES—Economic Study Issues
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OBJECTIVES: This paper presents a model based on real
option analysis for the valuation of R&D in the phar-
maceutical sector both for start-up ventures as well as big
conglomerates. We derive a formal compound option
model to value New Drug Applications (NDA) and show
the valuable contribution of real option analysis com-
pared to conventional DCF-analysis. METHODS: The
key understanding is that R&D projects of NDAs can be
seen as compound options. The growth option frame-
work looks at pharmaceutical investment projects as a
sequence of options, which differs from a conventional
DCF-analysis by incorporating the possibility to stop 
the project when a subsequent phase is not valuable
(abandon the option), and only continues with the project
(exercising the option) when it is valuable. Traditional
valuation techniques as DCF-analysis fail in valuing 
innovative companies because most of the value of R&D
projects is embedded in unexercised real options whose
future value is uncertain at this moment. If one considers
a company as a portfolio of real options, one can value
the projects or the company based on a compound option
model. RESULTS: The compound option model reveals
that real option analysis can better incorporate the value
of a NDA than conventional DCF-analysis would reveal.
Real option analysis will better reﬂect the fundamental
value of the project or of the company, which cannot be
captured by DCF-analysis. CONCLUSION: The paper
presents a new methodology for valuing R&D of 
pharmaceutical companies based on compound option
models.
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OBJECTIVE: Develop methodology to create a more
globally informative, CE-based “valuation” that is useful
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in comparing interventions across diseases. METHODS:
Cost effectiveness ratios (CERs), presenting the ﬁnancial
cost per quality-adjusted life year saved, enable decision
makers to assess the value of health care products/services
in reducing misery as well as extending life. Although
CERs are valuable especially in comparing options for 
a given disease, decision makers have struggled in using
them to compare the value of alternatives across diseases.
For example, Garvey (2000) noted that the CER use of
sildenaﬁl in erectile dysfunction was favorable compared
with treatments in other diseases, such as renal dialysis
and coronary artery-bypass graft surgery in current liter-
ature. Garvey concluded that while the CER comparisons
were valid on the “local” (condition-speciﬁc) compari-
sons, they are problematic in “global” comparison across
diseases. This could be attributed to the failure of CER
to account for different degrees of medical necessity, base-
line utility, public health importance, and other relevant
issues. Manifold theory helps address the issues arising
from global versus local properties from a geometric 
perspective. Manifold theory provides an excellent 
mathematical model to develop a global, cost-effective
based valuation of interventions that can incorporate
dimensions, such as medical necessity while preserving
the local functionality of useful condition-speciﬁc CER
comparisons. RESULTS: Examples of two different man-
ifolds derived under different assumptions are presented.
The development of the ﬁrst manifold is derived via the-
oretical criteria for rational health resource allocation,
while the second manifold is based on empirical data that
infer “rules at work” in the decision-making coverage for
the U.S. Medicare system. Calculations of global valua-
tions for renal dialysis, cholesterol-lowering medication
and coronary artery bypass graft surgery are presented
and compared to that of sildenaﬁl. CONCLUSIONS: The
resultant values, presented side-by-side with published
CER’s present a more globally interpretable “valuation”.
PMD7
VALUATION OF INFORMAL CARE:THE
OPPORTUNITY COST METHOD APPLIED IN
CAREGIVING FOR STROKE AND RHEUMATOID
ARTHRITIS PATIENTS
Van den Berg B1, Brouwer W2,Van Exel J2,
Koopmanschap M2
1Erasmus University and National Institute for Public Health
and the Environment, Rotterdam, Netherlands; 2Erasmus
University, Rotterdam, Netherlands
OBJECTIVES: Informal care, deﬁned as care provided by
family members or friends, plays a substantial role in the
total care provided to patients with chronic and terminal
diseases. It should be incorporated in any economic eval-
uation adopting the societal perspective. In practice
however, informal care is often neglected. Time is a sub-
stantial part of informal care. The time spent on caring
should be valued to incorporate it in economic evalua-
tions. It is recommended to value informal care time with
the opportunity cost method. We discuss the practical
problems of the application of the opportunity cost
method in caregiving for stroke and rheumatoid arthritis
patients. METHODS: The data for this study are col-
lected by mailed surveys to 217 informal caregivers of
stroke patients and to 153 informal caregivers of rheuma-
toid arthritis patients. RESULTS: We distinguished three
types of forgone time: paid work, unpaid work and
leisure. Informal care is usually at the cost of leisure (60
percent). In stroke however it is also for a major part at
the cost of unpaid work (36 percent). The total amount
of time forgone is in both populations approximately 5
hours a week of unpaid work and in case of stroke more
than 10 hours a week of paid work. The leisure time
forgone in rheumatoid arthritis is twice the leisure time
forgone in stroke. It is worth noting that we developed 
a new instrument to measure the opportunity costs of
informal care to rheumatoid arthritis. CONCLUSIONS:
Rheumatoid arthritis is an inﬂammatory progressive
chronic disease without a clear reference point. A 
reference point means that there is a clear period before
the incidence of the illness and a clear period after the
incidence. This lack of a reference point has important
implications for the measurement of time forgone in order
to be able to provide informal care.
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OBJECTIVES: The suitability and the practicality of
using different data sources in economic evaluation have
been well documented. The objective of this study was 
to identify any trends in the types of data sources used 
in these studies over a 6-year period (1995–2000)
METHODS: For this preliminary study, the area of heart
disease was selected to create a sample of papers for
analysis. A simple search strategy was constructed and
run on the NHS EED database. The retrieved studies were
then sorted by year and type of economic evaluation. The
sources of data used to estimate effectiveness, resource
use and costs for the interventions or programmes in the
studies were then identiﬁed for each study. RESULTS:
The literature search retrieved 326 economic evaluations
published between 1995 and 2000. Data used in the eval-
uations ranged from solely expert opinion to pragmatic
trials where cost and resource use information were 
collected alongside one another. There is a downward
trend in the proportion of studies using a retrospective
analysis to establish the effectiveness of interventions and
programmes. A review of the literature (with no meta-
analysis) has remained a constant data source for effec-
tiveness, accounting for approximately a quarter of all
evaluations each year. The type of resource utilisation
data used has not changed over the years, with the 
majority of information collected alongside trials, with
either the whole study population or with smaller
cohorts, or a retrospective analysis of case notes. The
